Navigation Links
Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
Date:7/22/2014

OXFORD, England, July 22, 2014 /PRNewswire/ --


Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®).  Based on these results, the company intends to transfer the formulation production process to a contract manufacturing organisation (CMO), and to advance Glide octreotide delivered with the needle-free Glide solid dose injector (SDI®) into clinical trials in 2015.

The pre-clinical study compared the pharmacokinetic profile of the most widely used clinical dose of Sandostatin (100 mcg) with that of Glide's octreotide solid dose formulation.  The results demonstrated that there was no statistical difference between the two profiles (p<0.05).  Octreotide products are currently approved for use in the treatment of acromegaly and certain neuroendocrine tumours with the market for immediate release liquid formulations estimated to be in excess of $150 million.

Dr Mark Carnegie-Brown, Glide Pharma's CEO, commented, "These results represent a significant milestone, both in the development of our final clinical formulation for Glide octreotide and of our scale-up capabilities.  Together, these enable us to transfer the formulation manufacturing process to a CMO later in the year.  This progress is mirrored in our device scale-up programme, and as a result we plan to complete an octreotide clinical proof-of-concept study with our Glide SDI® device in 2015."

About Glide Pharma 

Glide Pharma is a pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines.  The company's products are based on its proprietary solid dose injector, the Glide SDI®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines.  Glide's pipeline includes octreotide, parathyroid hormone and anthrax and influenza vaccines.

The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors.  Glide Pharma has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.  For more information please visit http://www.glidepharma.com.

Contacts
Dr Mark Carnegie-Brown
Chief Executive
Glide Pharma
Tel: +44(0)1235-577120

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241

Richard Bungay
Chief Financial Officer
Glide Pharma
Tel: +44(0)1235-577120


'/>"/>
SOURCE Glide Pharma
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
2. Verathon, maker of GlideScope video laryngoscopes, provides free educational DVD to promote best practices in pediatric airway management.
3. Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development
4. TriReme Medical and Japanese Partner Century Medical, Inc., Receive Shonin Approval for GliderXtreme PTA Catheter in Japan
5. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
6. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
7. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
8. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
9. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
10. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... The report " Automated Breast Ultrasound System (ABUS) Market ... End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook (U.S., ... , Germany , UK, France , ... , China , Japan , ... Saudi Arabia , UAE, South Africa ), ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is proud ... Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror Beauty ... by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a safe ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health ... Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage ... is an exciting addition to our provider network, and the addition will benefit ...
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey firm ... is launching a charity drive to raise awareness of heart disease and promote habits ... America, and is responsible for 1 in every 4 deaths at the national level ...
Breaking Medicine News(10 mins):